Studies have shown that using HDAC inhibitors like belinostat and trichostatin A (TSA) in combination with anti-CTLA-4 therapy can reduce the number of Tregs and increase the production of IFN-γ by tumor-reactive CD8+ T cells in the TME [408,409]. Here, HDAC9 is linked to neoplasm.